Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.